Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Methods Mol Biol. 2020;2058:133–154. doi: 10.1007/978-1-4939-9794-7_9

Figure 6: Treatment schema for intratumoral administration of rNDV-4-1BBL in a B16-F10 murine melanoma tumor model.

Figure 6:

Bilateral flank tumor models were established by injecting C57BL/6 mice with 2 × 105 B16-F10 cells in the right flank intradermally (i.d.) on day 0 and 1 × 105 cells in the left flank on day 4. On days 7, 9, 11 and 13, mice were treated with four 100 μL intratumoral injections of rNDV-4-1BBL in 1X PBS (1 × 107 pfu). On day 15 the animals were euthanized and the tumors were processed for analysis of tumor-infiltrating lymphocytes.